AstraZeneca withdraws application for lung cancer drug in EU
AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
EU Drug Regulator to Review Ozempic’s Possible Link to Eye Condition
The European Union’s drug regulator said it would review two studies that link Novo Nordisk’s blockbuster diabetes drug ...
AstraZeneca, Daiichi pull EU marketing application for lung cancer drug, Dato-DXd
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) withdraw EU marketing application for lung cancer therapy Dato-DXd. Read more ...
European markets higher in shortened session ahead of Christmas; Novo Nordisk resumes recovery
Novo Nordisk resumed its rally on Tuesday, rising to the top of the Stoxx 600 during early deals and adding 5.7% by 11:05 a.m ...
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU
AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision followed ...
Anavex receives EMA filing acceptance for treatment of Alzheimer’s disease
Life Sciences announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorization Application, ...
FTSE 100 Edges Higher In Thin Holiday Trade
U.K. stocks were moving higher on Tuesday in thin-shortened trading session for Christmas Eve. Markets will remain shut on Wednesday ...
PharmiWeb6d
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib)
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months f ...
BioSpace6d
EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters
Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have ...
European agency endorses approval of Biocon Biologics’ biosimilar Ustekinumab
BENGALURU: Biocon Biologics, a biosimilars company and subsidiary of Biocon, has announced that the European Medicines Agency ...
MT Newswires on MSN6h
Most European Bourses Track Higher Midday of Muted Tuesday Trading, Ahead of Holiday Break
Most European bourses were ahead midday Tuesday, though trading activities were muted as global markets are set to remain closed on Wednesday for the holiday. In corporate news, AstraZeneca (AZN) and ...